SCHEMBL5271997

SCHEMBL5271997

Cc1[nH]nc(-c2cc(Cl)c(O)c(Cl)c2O)c1-c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.53
GPR55 Q9Y2T6 5/20 0.52
CNR1 P21554 4/20 0.52
CNR2 P34972 4/20 0.52
KMT2A Q03164 6/20 0.51
MAPT P10636 5/20 0.51
MEN1 O00255 5/20 0.51
NPSR1 Q6W5P4 4/20 0.51
MAPK1 P28482 4/20 0.51
ALOX15 P16050 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
ALOX12 P18054 2/20 0.51
CYP2C19 P33261 2/20 0.51
HTT P42858 2/20 0.51
GAA P10253 2/20 0.51
GYS1 P13807 1/20 0.51
TP53 P04637 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395893 0.90 HSP90AA1 (0.56) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL5270606 0.84 HSP90AA1 (0.73) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL5269762 0.75 MAPT (0.75) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL14395874 0.75 GPR55 (0.60) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL30204288 0.75 MAPT (0.75) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL12768356 0.75 GYS1 (0.75) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL5269217 0.75 HSP90AA1 (0.78) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL11192094 0.73 AKT2 (0.68) GPR55CNR1CNR2KMT2AMAPT
SCHEMBL5268614 0.72 GYS1 (0.59) HSP90AA1GPR55CNR1CNR2KMT2A
SCHEMBL24964988 0.71 IKBKB (0.58) GPR55CNR1CNR2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885GPR55 715/4885CNR1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.